Opinion/decision on a Paediatric investigation plan (PIP): Pombiliti, Cipaglucosidase alfa, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Congenital, familial and genetic disorders, PIP number: EMA/PE/

Submitted by Anonymous (not verified) on 5 March 2026 - 15:25

Opinion/decision on a Paediatric investigation plan (PIP): Pombiliti, Cipaglucosidase alfa, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Congenital, familial and genetic disorders, PIP number: EMA/PE/0000223351

Human medicines European public assessment report (EPAR): Toujeo (previously Optisulin), insulin glargine, Date of authorisation: 26/06/2000, Revision: 38, Status: Authorised

Submitted by Anonymous (not verified) on 5 March 2026 - 14:52

Human medicines European public assessment report (EPAR): Toujeo (previously Optisulin), insulin glargine, Date of authorisation: 26/06/2000, Revision: 38, Status: Authorised

Human medicines European public assessment report (EPAR): Apidra, insulin glulisine, Date of authorisation: 27/09/2004, Revision: 35, Status: Authorised

Submitted by Anonymous (not verified) on 5 March 2026 - 14:48

Human medicines European public assessment report (EPAR): Apidra, insulin glulisine, Date of authorisation: 27/09/2004, Revision: 35, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness